The global proteomics market was valued at an estimated USD 24.29 billion in 2023 and is projected to grow at a compound annual growth rate (CAGR) of 13.10% from 2024 to 2030. Several key factors are contributing to this robust market growth, including the rising prevalence of chronic and infectious diseases, an increasing demand for rapid and advanced diagnostic solutions tailored to specific diseases, and a growing interest in personalized medicine. Additionally, technological advancements in protein analysis are further propelling this market forward.
The increasing incidence of chronic and infectious diseases is a significant driver of growth within the proteomics market. According to predictions from the World Health Organization (WHO), there will be over 35 million new cancer cases by 2050, marking a staggering 77% increase from the approximately 20 million cases estimated in 2022. This surge in disease prevalence is expected to heighten the demand for research focused on pathogenesis, advanced diagnostics, and innovative therapeutics. For example, a study published in Nature Communications in July 2024 highlighted the use of a proteomics-based approach to identify effectors secreted by Rickettsia spp., thereby enhancing our understanding of the host-pathogen interface.
Gather more insights about the market drivers, restrains and growth of the Proteomics Market
Moreover, a recent study featured in Nature Medicine in August 2024 showcased the development of a proteomic aging clock utilizing plasma proteins. This innovative tool measures biological age and predicts the risk of age-related diseases, multimorbidity, and mortality across diverse populations. Furthermore, emerging technologies such as top-down proteomics are playing a crucial role in elucidating the functions of proteoforms in disease mechanisms and precision medicine, effectively bridging the gap between genotypes and phenotypes.
Technology Segmentation Insights
Within the market, the spectrometry segment emerged as the largest revenue contributor in 2023 and is expected to expand at the highest CAGR of 14.77% during the forecast period. Spectrometry technology is integral for the identification and characterization of proteins, detection of post-translational modifications, and analysis of protein-protein interactions in proteomics studies. Advancements in mass spectrometry technology, including improved resolution, enhanced speed, and increased automation, have significantly bolstered its efficiency, making it a preferred tool for proteomics research. Additionally, the integration of spectrometry techniques with bioinformatics for data analysis has broadened its applications in drug discovery, biomarker identification, and personalized medicine. These advancements are anticipated to further drive the growth of the segment over the coming years.
The next-generation sequencing (NGS) segment is also projected to experience significant growth from 2024 to 2030. The decreasing costs associated with sequencing technologies have made NGS more accessible for a wider array of research and clinical applications. This reduction in costs, combined with technological advancements that have increased both the speed and accuracy of sequencing, is facilitating broader adoption across various fields, including oncology, genetic disease research, and personalized medicine. Companies in the proteomics market are actively responding to this rising demand through strategic initiatives. For instance, in February 2024, Pixelgen Technologies entered into a non-exclusive agreement with Japan's BioStream Co. Ltd to distribute its innovative next-generation sequencing spatial proteomics tools designed for single-cell analysis. Such initiatives are likely to significantly boost the growth of the NGS segment in the proteomics market.
Order a free sample PDF of the Market Intelligence Study, published by Grand View Research.
